Abstract 16-Membered meta, para-cyclophanes mimicking the vancomycin binding pocket (D-O-E ring) are designed and synthesized. The structural features of these biaryl ether containing macrocycles are: a) the deletion of the carboxyl group of vancomycin's central amino acid (amino acid D); b) the elongation of the N-terminal; c) the presence of lipidated aminoglucose at the D-ring. Cycloetherification by way of an intramolecular nucleophilic aromatic substitution reaction (S N Ar) is used as a key step for the construction of the macrocycle. Minimum inhibitory concentrations for all of the derivatives are measured using a standard microdilution assay. Compounds 2aϳ2c and 3aϳ3c displayed weak activities against resistant strain Enterococcus faecalis L560 and were inactive against Enterococcus faecium resistant strain L2215.
Introduction
For over a quarter of century, vancomycin ( Fig. 1) was one of the few antibiotics of the last resort for the treatment of infections due to methicillin-resistant Staphylococcus aureus and other Gram-positive organisms in patients allergic to b-lactam antibiotics [1] . Unfortunately, resistance to drugs of the vancomycin family has been recognized in the late 1980s and the frequency of resistance has increased significantly over the past decades, reaching 30% among hospitalized patients in 2002 in the USA. Since vancomycin-resistant enterococci (VRE) also carry resistance to virtually all other known antibiotics, it represents a serious threat to public health [2, 3] . depsipeptide that binds only weakly to the drug. In fact, in vitro binding studies have shown that the affinity of vancomycin for N-Ac-D-Ala-D-Lac is about 1000 times less than its affinity for N-Ac-D-Ala-D-Ala, due to one missing hydrogen bond and the ground state repulsion between the two oxygen lone-pairs in the former complex. The reduced binding affinity translated into about 1000-fold reduced sensitivity of vancomycin-resistant bacteria to this drug ( Fig. 1) [4] .
Importance of the Structure of Vancomycin Binding Pocket in Designing Compounds Active Against Vancomycin-resistant Enterococci (VRE)
Extensive structure-activity relationship (SAR) studies on vancomycin and teicoplanin type glycopeptide performed by both academic and industrial researchers indicated that the incorporation of a hydrophobic chain into the natural product is highly beneficial for activities against VRE [5, 6] . Indeed both oritavancin (LY333328) [7] and dalbavancin [8] , that entered into late-stage clinical trials, contain a hydrophobic group. Two theories have been proposed to account for oritavancin's bioactivity against VRE [1ϳ4]. Williams hypothesized that the presence of a lipid chain in the disaccharide part of vancomycin enhanced avidity for D-Ala-D-Lac by facilitating membrane anchoring and/or by promoting dimerization [9] . On the other hand, Kahne has recently advanced that oritavancin acts against VRE by direct interaction with the transglycosylase without substrate binding [10, 11] and evidences supportive to this view have been accumulated. We have been working on the design and synthesis of modified D-O-E ring of vancomycin and found that both the structure of the 16-membered macrocycle including the absolute configuration of the exo-cyclic stereocenter and the presence of a hydrophobic substituant (or a lipidated aminosugar) are important for the observed anti-VRE activities of our synthetic compounds [12ϳ14] . As a continuation of this research project, we report herein the synthesis and biological activity evaluation of compound series 2, 3. The characteristic structural feature of these compounds are as follows: a) the deletion of the carboxyl group of vancomycin's central amino acid (amino acid D); b) the elongation of the N-terminal; c) the presence of lipidated aminoglucose at the D-ring.
Results and Discussion

Synthesis of Macrocycles 2 and 3
Synthesis of the 16-membered meta, para-cyclophane 8 was accomplished as shown in Scheme 1. Coupling of 3,5- diisopropyloxy-4-methoxybenzylamine (4) with N-Boc-D-(4-fluoro-3-nitro)phenylalanyl-L-phenylalanine (5) [14] afforded dipeptide 6 in 89% yield. Treatment of 6 with BCl 3 led to the simultaneous deprotection of the isopropyl ether and the N-Boc function. Re-introduction of the Boc group furnished phenol 7 in 73% overall yield. The key intramolecular S N Ar-based cycloetherification of 7 was performed in DMSO (concentration of substrate: 0.01 M) in the presence of CsF at room temperature [15, 16] . Two separable atropisomers 8 and 9 were isolated in 65% overall yield (ratio 8/9ϭ3/2). The absolute configuration of the planar chirality of 8 and 9 was deduced from detailed NOE studies. Thus, the NOE correlation between protons H a /H c was observed in the NOESY spectrum of 8, indicative of the P-configuration of this atropstereoisomer. On the other hand, a H b /H c correlation, a characteristic of the M-atropstereoisomer, was observed for compound 9 [17] .
Conversion of 8 to 2c was shown in Scheme 2. Removal of N-Boc function under mild acidic conditions afforded the free amine 10 that was coupled directly with D-N-Boc Leu (11) to furnish, after saponification, the tripeptide 12 in 63% yield. The N-deprotection followed by coupling with 2 equivalents of N-Boc glycine provided compound 13 in 83% yield. Saponification of ester (LiOH, THF/H 2 Oϭ3/1) afforded then the free phenol 14 in 98% yield. KoenigsKnorr reaction [18] of 14 with freshly prepared 3,4,6-tri-Oacetyl-2-N-lauroyl-2-amino-2-deoxy-D-glucopyranosyl bromide (15) under phase transfer conditions (10% aqueous Na 2 CO 3 , nBu 4 NHSO 4 , CH 2 Cl 2 , rt) [19] afforded the desired b -glucoside 16 as the only isolable stereoisomer in 76% yield. Hydrolysis of acetate followed N-deprotection afforded compound 2c in 80% yield. Compounds 2a and 2b (Fig. 2) were obtained by cleavage of N-protecting groups from 14 and 13, respectively, under mild acidic conditions (TFA, CH 2 Cl 2 , rt).
Since we have previously demonstrated that the stereochemistry of the exo-cyclic chiral center has great influence of macrocycle's bioactivities [12ϳ14], compounds 3aϳ3c (Fig. 2) have also been synthesized following the same synthetic scheme using L-leucine as coupling partner.
Antibiotic Activity Evaluation
Minimum inhibitory concentrations for these compounds as well as reference compounds (vancomycin, teicoplanin) are measured using a standard microdilution assay. The selected results are summarized in Table 1 . For the sake of comparison, the anti VRE activities of previously synthesized compounds 17 and 18 ( Fig. 3) were also enlisted in the same table [14] . As it is seen, compounds 2aϳ2c and 3aϳ3c displayed poor activities against resistant strain Enterococcus faecalis L560 and were inactive against clinically more relevant E. faecium resistant strain L2215.
Compounds 2 and 3 were designed based on following reasoning: a) the deletion of the carboxyl group of the vancomycin's central amino acid D (cf. Fig. 1 ) to avoid the unfavorable electrostatic interaction with the modified peptidoglycan terminal D-Ala-D-Lac [20, 21] ; b) the Nterminal was elongated in order to introduce an additional hydrogen-bonding with D-Ala-D-Lac [22] . In order to explore the possible conformational effect, hence the relative three-dimensional orientation of NHs, compound 2 and 3 having D-Leucine (found in vancomycin), and D-leucine, respectively, were synthesized; the glycine was attached to leucine terminal in order to incorporate depicted in the Fig. 4 . In contrast to compounds 17 and 18 ( Fig. 3 ) that displayed potent activities against VRE (entry 7, 8), both 2 and 3 were relatively impotent against the same resistant strains. Since both 2c (3c) and 17 (18) contained the same lipidated aminoglucose at the same position and they differed only in the structure of the central amino acid (segment D), the present results reinforced our previous conclusion regarding the importance of the structure of the macrocycle in searching for compounds active against VRE.
Conclusion
In summary, we have designed and synthesized molecules of a general structure (2 and 3) in which the carboxylic acid group of vancomycin's central amino acid D was deleted and the N-terminal was elongated. These compounds including 2c and 3c with a lipidated aminoglucose at the Dring displayed only weak activity against E. faecalis resistant strain and were inactive against clinically more relevant E. faecium resistant strain. We have previously demonstrated, by detailed SAR studies, the importance of the hydrophobic chain in the active compounds, we shown here that the structure of macrocycle is equally important in searching for compounds active against VRE.
Experimental
General Methods
Melting points were recorded using Reichert melting point apparatus. Infrared spectra were recorded on a Nicolet 205 FT-IR spectrometer. NMR spectra were performed on a Bruker AC-300 (300 MHz) spectrometer. Mass spectra were obtained from an AEI MS-9 using electron spray (ES). Optical rotation was measured on a Jasco P-100 polarimetre.
Compound 4
To a solution of 3,5-diisopropyloxy-4-methoxy benzyl alcohol (1.21 g, 4.76 mmol) [17] in toluene/CH 2 Cl 2 (3 : 1, 24 ml) was added PBr 3 (0.48 ml, 4.76 mmol) at 0°C, and the mixture was stirred at r.t. for overnight. The reaction was quenched with water, and extracted with ether. The ether layer was washed with sat. NaHCO 3 and brine successively, dried over Na 2 SO 4 . The solvent was concentrated and the residue was purified by column chromatograph (SiO 2 , eluant: heptane/EtOAcϭ15/1) to give the bromide (1.38 g, 92% 
Compound 13
To a solution of compound 12 (45 mg, 0.063 mmol) in CH 2 Cl 2 (2.0 ml) was added TFA (1.0 ml) at 0°C. After being stirred at the same temperature for 1.0 hour, the reaction mixture was concentrated to dryness under vacuum to afford amine which was directly used for next reaction. To a solution of amine and N-Boc glycine (26 mg, 0.15 mmol) in DMF (3 ml) was added DIPEA (44 m l, 0.25 mmol) and HATU (60 mg, 0.16 mmol). The reaction mixture was stirred at room temperature for 12 hours before it was extracted with EtOAc. The organic phase was washed with 5% aqueous HCl, saturated NaHCO 3 , brine, dried over Na 2 SO 4 , and concentrated under vacuum. 
Compound 16
To a solution of 1,3,4,6-tetra-O-acetyl-2-N-lauroyl-2-amino-2-deoxy-2-D-glucopyranose (85 mg, 0.16 mmol) in AcOH (2 ml) was added 33% HBr/AcOH (0.9 ml) at room temperature [14] . After being stirred for 3 hours at room temperature, the reaction mixture was diluted with icewater and it was extracted with CH 2 Cl 2 . The combined organic phases were washed with cooled aqueous NaHCO 3 and brine. The solvent was concentrated to about 1 ml under vacuum below 30°C and the resulting solution was immediately used for next reaction. To the above solution was added compound 14 (18 mg, 0.023 mmol), 10% aqueous Na 2 CO 3 (1.0 ml) and catalytic amount of (nBu) 4 NHSO 4 . After being stirred at room temperature for 4 hours, the reaction mixture was acidified with citric acid to pH 4ϳ5 and the two phases were separated. SO 4 , and concentrated under vacuum to afford compound acid, which proved to be of sufficient purity and was used directly for next step. To a solution of above acid in CH 2 Cl 2 (1.0 ml) was added TFA (0.5 ml) at 0°C. After being stirred at the same temperature for 1.0 hour, the reaction mixture was concentrated to dryness under vacuum to afford compound 2c (13 mg, 80% , 1H), 3.89 (m, 1H), 3.86 (s, 3H) 
